Leukocyte News and Research

RSS

Gene defects could become targets for new personalised treatments for bowel cancer

Cancer Research UK-funded scientists have discovered that the gene defects that cause some bowel cancers could become the targets for new personalised treatments. Their research is published in Cancer Cell today (Monday).

16 Mar 2010

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).

15 Mar 2010

Challenges in treating AML and recent updates to NCCN Guidelines presented at NCCN Annual Conference

Using risk stratification to assist in treatment selection was just one of the focal points at a recent presentation of the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Acute Myeloid Leukemia (AML) at the NCCN 15th Annual Conference.

15 Mar 2010

Fewer injections to treat neutropenia in childhood cancer patients

For patients like 10-year-old Sabrina Jo Spence, new research led by St. Jude Children's Research Hospital investigators meant fewer injections to combat the drop in white blood cells following her recent chemotherapy.

11 Mar 2010

Genetic mutation in African-American men with family history of prostate cancer discovered

Shahriar Koochekpour, MD, PhD, Assistant Professor of Microbiology and Immunology, Biochemistry and Molecular Biology, and Genetics at LSU Health Sciences Center New Orleans, led research that has discovered, for the first time, a genetic mutation in African-American men with a family history of prostate cancer who are at increased risk for the disease.

11 Mar 2010

TNS acquires license to Ergothioneine Transporter from University of Cologne

Total Nutraceutical Solutions, Inc. announced that the company has acquired from the University of Cologne, Cologne, Germany, an exclusive license agreement on the invention entitled “Ergothioneine Transporter,” owned by the University.

10 Mar 2010

Endothelial cells can produce copious amounts of adult stem cells: Study

In a leap toward making stem cell therapy widely available, researchers at the Ansary Stem Cell Institute at Weill Cornell Medical College have discovered that endothelial cells, the most basic building blocks of the vascular system, produce growth factors that can grow copious amounts of adult stem cells and their progeny over the course of weeks.

5 Mar 2010

Researchers discover key reason why form of leukemia progresses from chronic phase to blast crisis

Researchers have discovered a key reason why a form of leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis.

5 Mar 2010

South West Liver Unit researchers receive grants for developing Hepatitis C vaccine

Researchers at the South West Liver Unit, based at Plymouth Hospitals NHS Trust and supported by the Peninsula Medical School, are working to save more lives and improve the health of Hepatitis C sufferers around the world by developing a vaccine for the disease.

5 Mar 2010

Severe inflammatory diseases: Blocking "death messenger" might be a promising treatment

The signaling molecule CD95L, known as "death messenger," causes an inflammatory process in injured tissue after spinal cord injuries and prevents its healing. This discovery was published by scientists of the German Cancer Research Center. In mice, the researchers found out that if they switch off CD95L, the injured spinal cord heals and the animals regain better ability to move. Therefore, substances which block the death messenger might offer a new approach in the treatment of severe inflammatory diseases.

4 Mar 2010

Cyntellect to provide LEAP Cell Processing Workstation to Harvard University and HHMI researchers

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, has entered into an agreement with Harvard University and the Howard Hughes Medical Institute to provide their researchers with the LEAP™ Cell Processing Workstation.

3 Mar 2010

Simvastatin impairs ability of macrophages to kill pathogens, and enhances cytokine production

Simvastatin might help us control our cholesterol, but when it comes to infection, it's an entirely different story says a new research study published in the Journal of Leukocyte Biology. In the research report, scientists from Italy show that simvastatin delivers a one-two punch to the immune system. First it impairs the ability of specialized immune cells, called macrophages, to kill pathogens. Then, it enhances production of molecules, called cytokines, which trigger and sustain inflammation.

2 Mar 2010

Researchers proceed to develop vaccination to reverse neurological damage seen with Parkinson's disease

Researchers at the University of Nebraska Medical Center have taken a significant step forward in developing a vaccination approach to reverse the neurological damage seen with Parkinson's disease.

2 Mar 2010

Salmonella-infected mice help understand how symptoms of HLH develop

A new University of Colorado at Boulder study shows mice infected with the bacteria salmonella develop clinical signs consistent with a deadly and poorly understood human inflammatory disease, a finding that may lead to new therapies.

26 Feb 2010

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

HIV/AIDS remains one of the world's most significant public health challenges, particularly in developing countries. The Human Immunodeficiency Virus (HIV-1), the variant responsible for the pandemic, has the ability to infect different cell types such as T cells, macrophages and dendritic cells (DC). These latter cells are crucial in the defense against infectious agents and play a major role in viral pathogenesis.

25 Feb 2010

Signaling molecules may link certain actions of B cells to solid tumor growth: Study

Cancer researchers studying the immune system have identified a previously unrecognized set of targets and biomarkers to battle solid tumors.

25 Feb 2010

New treatments for heart disease

Two studies published in the latest issue of Cell Transplantation (18:12) may lead to new treatments for the treatment of heart diseases. The first study, carried out by a team of Brazilian researchers, found that cell transplantation of bone marrow mononuclear cells (BMMCs) directly into the heart benefited patients suffering from refractory angina.

24 Feb 2010

Scientists develop new mathematical model to understand CML better

Doctors can now understand better chronic myeloid leukaemia (CML), including how it responds to therapy, thanks to a new mathematical model for the disease, developed by scientists in Portugal, Belgium and the United States. The work, to be published in the June edition of the journal Haematologica, also reveals that current therapies - which are not believed to cure CML - with the right protocol can actually get rid of the disease, and provides guidelines on how to do that.

21 Feb 2010

FDA approves Rituxan-FC combination therapy for CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec announced today the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).

18 Feb 2010

Rituxan, intended for patients with CLL receives FDA approval

The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.

18 Feb 2010

Leukocyte News and Research

Gene defects could become targets for new personalised treatments for bowel cancer

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

Challenges in treating AML and recent updates to NCCN Guidelines presented at NCCN Annual Conference

Fewer injections to treat neutropenia in childhood cancer patients

Genetic mutation in African-American men with family history of prostate cancer discovered

TNS acquires license to Ergothioneine Transporter from University of Cologne

Endothelial cells can produce copious amounts of adult stem cells: Study

Researchers discover key reason why form of leukemia progresses from chronic phase to blast crisis

South West Liver Unit researchers receive grants for developing Hepatitis C vaccine

Severe inflammatory diseases: Blocking "death messenger" might be a promising treatment

Cyntellect to provide LEAP Cell Processing Workstation to Harvard University and HHMI researchers

Simvastatin impairs ability of macrophages to kill pathogens, and enhances cytokine production

Researchers proceed to develop vaccination to reverse neurological damage seen with Parkinson's disease

Salmonella-infected mice help understand how symptoms of HLH develop

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

Signaling molecules may link certain actions of B cells to solid tumor growth: Study

New treatments for heart disease

Scientists develop new mathematical model to understand CML better

FDA approves Rituxan-FC combination therapy for CLL

Rituxan, intended for patients with CLL receives FDA approval

Immunology eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News